Can 2015 Winners AFC Energy plc (+280%), Quindell PLC (+212%) And Tiziana Life Sciences PLC (+172%) Continue To Rocket?

Are there further big gains to come for investors in AFC Energy plc (LON:AFC), Quindell PLC (LON:QPP) and Tiziana Life Sciences PLC (LON:TILS)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares of AFC Energy (LSE: AFC), Quindell (LSE: QPP) and Tiziana Life Sciences (LSE: TILS) have rocketed since the start of the year. Are the fireworks over, or can these three stocks continue to soar?

AFC Energy

AFC Energy, which listed on the AIM Market in 2007, describes itself as “the world’s leading developer of low-cost alkaline fuel cell technology”. The company is focused on large-scale industrial applications.

AFC’s POWER-UP project aims to demonstrate the world’s largest alkaline fuel cell system at an industrial gas plant in Stade, Germany. The project represents the final phase of pre-commercialisation development, and, if successful, will create a platform for global commercial deployment. The schedule is ambitious, but newsflow has been good, and the shares — which had been languishing at under 10p — are currently trading at 39p, valuing the company at £120m.

Further news that the project is on track — including initial power production at Stade in July — could see the shares rise further. The outcome of full testing targeted for December is the biggie. Given the size of the commercial opportunity, a validation of AFC’s technology on an industrial scale could see the valuation of the company rise steeply.

Quindell

Quindell was one of the most heavily-shorted shares in 2014, but anyone buying in at sub-40p lows at the back-end of the year has seen a spectacular increase in 2015. The shares are currently trading at 125p, valuing the company at £545m.

Quindell is set to sell its problematic professional services division to Australian law firm Slater & Gordon (S&G) for an initial cash consideration of £637m. The deal — which is subject only to approval by the Financial Conduct Authority (FCA) — digs Quindell out of a hole, caused by aggressive accounting and lower than anticipated cash flows. Quindell’s new management expects to be able to pay down debt, retain enough cash for investment in the retained business, and return up to £500m to shareholders.

So, assuming a £500m return, the market is currently valuing what remains of Quindell at just £45m. This consists of a core of telematics-related businesses (for which the company is rumoured to have rejected a £50-£60m offer), some non-core operations that are up for sale, and an entitlement to a share of future settlement fees from a portfolio of hearing-loss claims that passed to S&G.

Quindell is set to publish re-stated accounts by the end of June. If management can demonstrate that “new” Quindell is worth more than the £45m the market is currently valuing it at, the shares could rise accordingly. This could potentially come from one or more of the following: the performance of the telematics businesses (or an offer for them), cash realised from the sale of non-core businesses, and news on hearing-loss fees. Confirmation of the expected FCA approval for the S&G deal and a firm commitment by Quindell’s management to return cash to shareholders at the top end of the proposed “up to £500m” are other potential catalysts for the shares to move higher.

Tiziana Life Sciences

This clinical stage biotech company listed on AIM just over a year ago through a reverse takeover. The company is focused on discovering and developing novel molecules for the treatment of metastatic cancers (cancers that spread from the primary site to other parts of the body). The company’s initial research programme is targeting therapeutics for late-stage breast cancer.

Tiziana has identified an inhibitor candidate and is seeking to discover further molecules with improved profiles. The company is aiming to select a clinical candidate in the fourth quarter of this year, and to be ready to prepare and submit a US New Drug Application in the fourth quarter of 2016. Tiziana has other assets — most recently the acquisition of an exclusive licence for a novel anti-cancer stem cell agent — and the shares have risen strongly in recent months: they currently trade at 135p, valuing the company at £125m.

The valuation of biotech businesses always involves considerable speculation, and I’m not sure Tiziana — which looks like it’s going to burn cash for as far ahead as the eye can see — merits a £125m tag at this stage. Which is not to say the shares can’t go higher in anticipation of positive newsflow. Speculation and momentum can often drive the shares of this type of company in the short term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Google office headquarters
Investing Articles

1 reason I like buying S&P 500 shares – and 1 reason I don’t

Will this investor try to improve his potential returns by focusing more on S&P 500 shares instead of British ones?…

Read more »

Young woman holding up three fingers
Investing Articles

3 SIPP mistakes to avoid

Our writer explains a trio of potentially costly errors he tries to avoid making when investing his SIPP, on an…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Here’s how (and why) I’d start buying shares with £25 a week

Our writer uses his investment experience and current approach to explain how he would start buying shares on a limited…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s my 5-step approach to earning passive income of £500 a month

Christopher Ruane explains the handful of steps he uses to target hundreds of pounds in passive income each month.

Read more »

Investing Articles

2 UK shares I’ve been buying this week

From a value perspective, UK shares look attractive. But two in particular have been attracting Stephen Wright’s attention over the…

Read more »

Investing Articles

A lifelong second income for just £10 a week? Here’s how!

With a simple, structured approach to buying blue-chip dividend shares at attractive prices, our writer's building a second income for…

Read more »

Investing Articles

Here’s how I’d use a £20k Stocks and Shares ISA to help build generational wealth

Discover how our writer would aim to turn a £20k Stocks and Shares ISA into a sizeable nest egg by…

Read more »